

REMARKS

Claims 1-27 are presently pending in the application.

The Examiner has required the election of: (i) the coated stent; (ii) the method of making the coated stent; or (iii) the method of treating or preventing cardiovascular disease or renal disease with the coated stent. In response, Applicants elect (i) the coated stent.

In addition, if (i) the coated stent is elected, the election of a class of JNK inhibitor from one of claims 4-6 is required. In response, Applicants elect the class of JNK inhibitor of claim 4.

Finally, the election of a specific inhibitor is also required. In response, Applicants elect without traverse 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole (*see* Specification at page 22, second compound), which has the following structure:



Claims 1-4 and 7-27 read on the elected species.

Applicants respectfully request that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response; however, in the event that any fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: May 9, 2007

Respectfully submitted,
Anthony M. Insogna, Reg. No. 35,203
By: Michael J. Bruner, Reg. No. 47,458
By: Michael J. Bruner (Reg. No. 47,458)
JONES DAY
222 East 41st Street
New York, New York 10017
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12265 El Camino Real, Suite 200
San Diego, California 92130
(858) 314-1130